Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized study of immunosuppressive regimens in marginal old-for-old renal transplant recipients
2004-001205-99Phase 3Completed
- Sponsor
- Fujisawa Pharmaceutical
- Start
- Jan 2005
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tacrolimus in kidney allograft rejection (2 arms), sponsored by Fujisawa Pharmaceutical. Primary endpoint: Safety and efficacy of tacrolimus-based regimens. Started Jan 2005; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2004-001205-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001205-99.